Attenuation of cardiopulmonary bypass–derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations  by Sawa, Yoshiki et al.
ATTENUATION OF 
CARDIOPULMONARY 
BYPASS-DERIVED 
INFLAMMATORY REACTIONS 
REDUCES MYOCARDIAL 
REPERFUSION IN JURY IN 
CARDIAC OPERATIONS 
In cardiac operations endopeptidase (protease) inhibitor may be beneficial 
in reducing myocardial injury when administered in the cardiopulmonary 
bypass prime. Nafamostat mesilate was evaluated in 20 patients who 
underwent coronary artery bypass grafting. The patients were divided into 
a control group (n = 10) and a nafamostat group (n = 10). Nafamostat (2 
mg/kg per hour) was continuously given during cardiopulmonary b pass in 
the nafamostat group. The age, number of grafts, cardiopulmonary b pass 
time, and aortic crossclamp time were similar between groups. In the 
control group, neither tumor necrosis factor-a nor interleukin-1 levels 
showed any significant change during cardiopulmonary b pass, whereas 
interleukin-6 and interleukin-8 levels, percent expression of adhesion 
molecule (CD18) on neutrophils, and CHs0 assay results increased signif- 
icantly during cardiopulmonary b pass. As compared with the control 
group, the nafamostat group showed significantly lower levels of interleu- 
kin-6 (123 - 57 versus 40 --- 22 pg/ml, respectively) and interleukin-8 (96 
--- 13 versus 66 - 14 pg/ml, respectively). The nafamostat group showed a 
significantly lower difference of CHso assay results and malondialdehyde 
levels between coronary sinus blood and arterial blood and peak values of 
creatine kinase MB (43 -+ 12 IU/L versus 19 -+ 6 IU/L) during the 
postoperative course compared with findings in the control group. These 
results demonstrated that inflammatory reactions induced by cardiopul- 
monary bypass had adverse effects on myocardial recovery after aortic 
crossclamping and that nafamostat mesilate given during cardiopulmonary 
bypass appeared to reduce myocardial reperfusion injury b attenuating 
such inflammatory reactions. Attenuation of inflammatory reactions of 
cardiopulmonary b pass hould be considered in the strategy of myocardial 
protection. (J THORAC CARDIOVASC SURG 1996;111:29-35) 
Yoshiki Sawa, MD, Yasuhisa Shimazaki, MD, Keishi Kadoba, MD, 
Takashi Masai, MD, Hirotsugu Fukuda, MD, Toshihiro Ohata, MD, 
Kazuhiro Taniguchi, MD, and Hikaru Matsuda, MD, Osaka, Japan 
A lthough the safety of cardiopulmonary bypass (CPB) has been elevated remarkably in recent 
years, prevention of postreperfusion syndrome includ- 
ing injuries to various organs after CPB has not yet 
been adequately achieved? -3 Recent studies uggested 
that complement is activated by CPB for cardiac 
operations~' 5 and that neutrophils and inflammatory 
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cytokines, which are closely involved in inflammation, 
can injure lungs and other organs during the course of 
CPB. 4-8 It is therefore plausible to imagine that inflam- 
matory cytokines, in addition to CPB-activated com- 
plement and neutrophils, are closely related to the 
onset of reperfusion i jury in myocardium. TM
We previously reported that nafamostat mesilate 
(FUT-175), which is a serine endopeptidase (pro- 
tease) inhibitor, suppressed the activation of com- 
plement and of the clotting and fibrinolytic system 
during CPB. 7 The present study was undertaken to 
analyze changes in inflammatory cytokines, as well 
as complement consumption and neutrophil activa- 
tion, during cardiac operations and to examine 
whether the antiinflammatory action of FUT-175 
would suppress changes in these cytokines and 
reduce myocardial injury. 
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Table I. Comparison ofthe pmoperative basic data 
between control and FUT-175 groups 
Group 
Control FUT-175 p Value 
No. 10 10 
Age (yr) 59 -+ 16 62 _+ 18 NS 
Grafts 3 _+ 0.5 2.5 _+ 0.5 NS 
AXC time (min) 105 +_ 20 98 +- 45 NS 
CPB time (min) 165 _+ 36 130 -+ 36 NS 
NS, Not significant; AXC, aortic rossclamp. 
Paticnts and methods 
The study subjects were 20 patients who underwent 
coronary artery bypass grafting at the Osaka University 
Hospital in 1993. All subjects gave informed consent, 
and the study was performed according to the guide- 
lines of our internal review board. The subjects were 
blindly divided at random into two groups: group C (10 
control patients who did not receive FUT-175 treat- 
ment) and group F (10 patients given FUT-175). Nei- 
ther the surgeon or the patient was informed as to the 
group to which the patient belonged. For group F 
patients, administration of FUT-175 was continued 
during CPB at a dosage of 2 mg/kg per hour. In terms 
of patient age, number of grafts, during of CPB, and 
duration of aortic crossclamping, there was no signifi- 
cant difference between the two groups (Table I). 
Arterial blood was sampled at five points (1 hour and 2 
hours after the start of CPB and immediately, and 2 and 
12 hours after the end of CPB). 
The basic method of myocardial protection was the use 
of cold potassium crystalloid cardioplegic solution as 
described before. 12 The initial dose of cardioplegic solu- 
tion was 10 ml/kg body weight, and a further half dose was 
infused every 30 minutes. Myocardial temperature was 
monitored at the ventricular septum and maintained at 
less than 15 ° C with topical cooling. The blood tempera- 
ture of CPB was maintained at 28 ° C, and a membrane 
oxygenator (Capiox-E, Terumo Co., Tokyo, Japan) 
primed without blood was used in all cases. 
Tumor necrosis factor-c~ (TNF-~), interleukin-1/3 
(IL-I/3), IL-6, and IL-8 levels in the blood were mea- 
sured by an enzyme-linked immunosorbent assay 
method using commercial kits (TNF-c~ and IL-l/3 kits, 
Otsuka Pharmaceutical Co., Tokushima, Japan; IL-6 
and IL-8 kits, Toray Fujibionics, Tokyo, Japan). The 
prevalence of adhesion molecule (CD18) expression on 
neutrophils was measured by flow cytometry. For this 
measurement, fluorescein isothiocyanate-labeled mono- 
clonal antibody anti-CD18 (MA-7953, Becton Dickinson, 
San Jose, Calif.) and flow cytometry (FACScan, Becton 
Dickinson) were used. Before aortic crossclamping and 10 
minutes after the release of the aortic crossclamp, CHs0 
assay levels by the one-point method (Kyowa Pharmaceuti- 
cal Co., Tokyo, Japan) and the level of the indicator of lipid 
peroxidation, malondialdehyde, by the ftuorescence methods 
(Wako Pharmaceutical, Osaka, Japan) were measured in 
coronary sinus and arterial blood. The value of each of these 
two parameters in arterial blood was subtracted from that in 
coronary sinus blood to yield the amount of total comple- 
ment activity and malondialdehyde originating from the 
myocardium. 12Furthermore, creatine kinase (CK) MB lev- 
els were measured. The maximum value of CK-MB level, 
recorded during the first 24 hours after operation, was 
compared between the two groups, a3 
As for the clinical data, the rate of spontaneous defi- 
brillation at the release of the aortic crossclamp and the 
maximum dose of dopamine required at weaning from 
CPB (expressed in micrograms per kilogram per minute) 
to maintain the arterial pressure higher than 80 mm Hg 
were compared; no other drugs including catecholamine 
and vasodilators were used during these periods. More- 
over, the percentage of ST segment elevation (more than 
1 mm) during the postoperative period and the duration 
of catecholamine support in the postoperative period 
were compared for the two groups. 
Results were expressed as mean plus or minus the 
standard eviation. For comparison of the significance of 
the difference between the two groups or of the data with 
the baseline data, a two-tailed unpaired t test was used. 
For comparison of multiple data within the group, the 
Newman-Keuls test was used. For the percentage rate of 
spontaneous defibrillation and ST segment elevation, the 
X a test was used. A value of p < 0.05 was regarded as 
statistically significant. 
Results 
Clinical results. All patients tolerated the surgi- 
cal procedures and SUlvived without significant com- 
plicadon related to this study. 
Inflammation caused by CPB. When the course 
of CH»o assay results and CD18 expr¢ssion on 
neutrophils in group C was followed, starting during 
CPB and ending 12 hours after completion of CPB, 
CD18 expression increased significantly and CH»0 
assay results decreased significantly during CPB. 
Both parameters had returrled to baseline levels by 
12 hours after the end of CPB (Fig. 1). 
When the course of IL-6 and IL-8 levels in group 
C was followed for the same period, both increased 
during CPB and had returned to baseline levels by 
12 hours after CPB (Fig. 2). IL-l/3 and TNF-c~ levels 
in group C showed no significant changes during 
CPB (Fig. 3). 
Suppression of CPB-caused inflammation by 
FUT-175. When the time course of IL-6 and IL-8 
levels was compared between group C and group F, 
both parameters, measured 2 hours after the start of 
CPB, were significantly lower in group F (IL-6, 41 + 
14 pg/ml; IL-8, 18 _+ 13 pg/ml) than in group C 
(IL-6, 79 + 16 pg/ml; IL-8, 49 + 21 pg/ml) (Fig. 4). 
Myocardial protection by FUT-I75. The differ- 
ences in both CH»0 assay finding and levels of 
malondialdehyde between coronary venous blood 
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Fig. 1. Course of CH»o assay results and CD18 expression on neutrophils during CPB. 
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Fig. 2. Course of IL-6 and IL-8 levels during CPB. 
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and arterial blood, as measured after the release of 
aortic occlusion, were significantly ower in group F 
than in group C (F versus C: CH»0, 0.4 _+ 0.1 IU/ml 
versus 2.2 +_ 0.1 IU/ml; malondialdehyde, 0.8_+ 0.2 
nmol/ml versus 1.4 + 0.2 nmol/ml) (Fig. 5). 
The ma~dmal CK-MB level within the first 24 
hours after operation was significantly lower in 
group F (19 _+ 6 IU/L) than in group C (43 _+ 12 
1U/L) (Fig, 6). 
Other clinical results (Table II). Group F had a 
significantly higher percentage of patients with 
spontaneous defibrillation after the release of the 
aortic crossclamp than group C. However, there was 
no significant difference in maximum dosage of 
dopamine required at weaning flora CPB, percent- 
age of ST segment elevation, and duration of cate- 
cholamine support in the postoperative p riod be- 
tween the two groups. 
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Fig. 4. Comparison of IL-6 and IL-8 levels between groups C and F. 
Discussion 
The results of the present study demonstrated 
that IL-6 and IL-8 levels increased uring CPB and 
decreased after the end of CPB, that CHso assay 
results decreased and CD18 expression increased 
throughout CPB until CPB was completed, and that 
FUT-175 treatment suppressed the CPB-stimulated 
production of these cytokines, myocardial comple- 
ment consumption, and MDA production resulting 
in a decrease of CK-MB loss from the myocardium 
and an increase in rate of spontaneous defibrillation 
after release of the aortic crossclamp. These results 
indicate that CPB causes activation of complement 
and neutrophils and enhances cytokine production 
and that endopeptidase (protease) inhibitors reduce 
CPB-caused injury to the myocardium by suppress- 
ing these changes. These inflammatory reactions 
during CPB coincided with those described in pre- 
vious reports. 14-]9 
Gillinov and associates is reported that neutrophils 
are more likely to be activated and express CD18 
during CPB because of some potent chemotactic fac- 
tors such as C5a, platelet activating factor, and leukot- 
riene B 4. However, no clinical reports of CPB-associ- 
ated neutrophil activation have been reported. In the 
present study, the increase in CD18 expression during 
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Fig. 5. Comparison of differences in CHso assay results and malondialdehyde (MDA)levels between 
coronary venous blood and arterial b ood between groups F and C.
Table II. Comparison of the results in ctinical data I U / L 
between control and FUT-175 groups ] O0 
Group 
P 
Control FUT-1 75 VaIue 
Spontaneous defibrillation (%) 20 80 <0.05 
Dopamine dose immediately 6.3 _+ 1.7 7.2 _+ 2.6 NS 
after CPB (/xg/kg/min) 
Dopamine-s~pported 4.5 _+ 2.1 3.8 _+ 2.9 NS 
postoperative period (days) 
ST segment elevation (%) 20 10 NS 
NS, Not significant. 
CPB was parallel to the chänge observed inCHso assay 
results. This finding is identical with the finding re- 
ported by iGillinov and associates. 15
Various reports have been published concerning 
CPB-caused enhancement of inflammatory cytokine 
producfion. Kawamura nd associates a6and Steinberg 
and associates 17reported that IL-6 levels increased 
during CPB and deceased after the end of CPB. 
Similar changes in levels of IL-8 have also been 
repo~:ted by Kawamura, !6Finn, 18 Laouar, 19 and their 
associates. These findings indicate that these inttam- 
matory cytpkines involved in the acute-phase reactions 
serve as p~omoters of CPB-associated inflammation. 
The relationshi p of the increase of these cytokines 
to CPB-aisociated injury of organs in the c!inical 
situation had only been reported by Laouar and 
co-worker~, 9 who reported that even when IL-8 
levels were reduced by methylprednisolone, utro- 
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Fig. 6. Comparison of maximal CK-MB levels (rnax CPK- 
MB) within first 24 hours after operation between groups 
F and C. 
phil infiltration into lungs could not be suppressed. 
In the present study, FUT-175 reduced the lev¢l of 
inflammatory cytokines with attenuation of reperfu- 
sion injury in myocardium. These results endorse 
our hypothesis that these cytokines may be related 
to reperfusion injury in myocardium. However, 
these clinical investigations have limitation and fur- 
ther experimental studies appear to be needed tO 
obtain direct evidence of the accuracy of our hy- 
pothesis. 
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Regarding the mechanism by which FUT-175 
suppresses cytokine production, it has been re- 
ported that FUT-175 inhibits the endopeptidase 
(protease) involved in the release of cytokines from 
cytokine,producing cells. 2° It is also known that 
FUT-175 directly suppresses the activity of comple- 
ment 21 and neutrophils. 22 On the other hand, FUT- 
175 protected reperfusion i jury in myocardium in
an experiment that used isolated hearts perfused 
with crystalloid solution, 23 which suggests hat it also 
inhibits proteases of a lysosome origin. 24 In the 
present study, FUT-175 was found to suppress in- 
flammatory eactions that involve complement con- 
sumption and decreased lipid peroxydation. It is 
plausible to imagine that suppression of these in- 
flammatory eactions resulted in decreased comple- 
ment consumption and decreased oxygen free radi- 
cal production by neutrophils in the heart after 
reperfusion, thus leading to a reduction of myocar- 
dial injury. 
Menaschè and colleagues 2 reported that IL-l/3 
and TNF-a production is induced by CPB and that 
their levels reach a peak 2 hours after CPB. 
However, Butler, 26 Steinberg, 17 Finn, 18 and their 
associates reported that neither IL-l/3 nor TNF-a 
levels showed any significant increase during CPB, 
which is similar to the results we obtained. This 
discrepancy may be associated with some factors 
such as the magnitude of surgical stress and the 
length of CPB or the difference in the assay 
method. It is also possible that IL-l/3 and TNF-a 
are produced in the late phase of the reaction, 
unlike IL-6 and IL-8, which increase during the 
acute phase, so that the production mechanism 
and origin of IL-l/3 and TNF-o~ may differ from 
those of IL-6 and IL-8. 
In summary, the present study suggests that (1) 
neutrophil activation and increases in complement 
consumption and levels of IL-6 and IL-8 were 
observed uring CPB, (2) myocardial malondialde- 
hyde production and compiement consumption i - 
creased after reperfusion after CPB, and (3) the 
increase in these inflammatory reactions in CPB and 
the leak of CK-MB from the myocardium were 
reduced when a protease inhibitor was administered 
during CPB. These results allow us to conclude that 
because inflammatory cytokine production is en- 
hanced uring CPB and causes aggravation ofmyo- 
cardial injury, suppression of inflammatory c tokine 
production is important in reducing reperfusion 
injury in myocardium. 
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